‹ ›
MYP_129168
← PREVIOUS NEXT → BACK
Basic Information
HCV gp (710-725)
Anticancer ▸ Cytotoxic anticancer activity ▸ Cytotoxic
Antimicrobial
Antiviral
Antiviral ▸ Anti-Hepatitis virus ▸ Anti-HCV
Antiviral ▸ Antiviral mechanism ▸ Viral entry inhibition
Toxicity / Safety ▸ Cytotoxicity ▸ Cytotoxic
Venom / Toxin ▸ General toxin ▸ Cytotoxic
Standard
16 amino acids
C101H152N18O21
Standard
Sequence
VSFAIKWEYVLLLFLL
Physicochemical Analysis
1954.40 Da
5.97
-0.27
-0.48
-0.0166
1.81
0.23
0.66
4.07
188.75
0.2500
6990.00
6990.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
619.39
3.42
22.0
21.0
61.0
140.0
5.0
15.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0106182 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral
hepatitis C virus(HCVpp):inhibition of virus infection in Huh-7 human hepatoma cells
0.3±0.4 μM
EC50
PaperPubMed PMID: 20156485 PMID20156485 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/20156485/
RECORD: Rec_0142904 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Protein-derived synthetic peptide
32630
Structure & Mods
synthetic linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-HCV Entry inhibition
Hepatitis C virus(HCVpp) | hepatoma cells
14±12 μM
EC90
Mammalian: 100 h; Yeast: >20 h; E. coli: >10 h
PaperA peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. | Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R. | Antiviral Res. 2010 May;86(2):172-9. | DOI:10.1016/j.antiviral.2010.02.316 | PMID:20156485 PMID20156485 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/20156485/
RECORD: Rec_0154363 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral Cytotoxic
PaperPubMed PMID: 20156485 PMID20156485 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/20156485/
RECORD: Rec_0184142 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral
Hepatitis C virus (HCV) PsV
70-80 % Inhibition
Inhibition
PMID20156485 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/20156485/
RECORD: Rec_0235749 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Protein-derived synthetic peptide
32630
Structure & Mods
synthetic linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Entry inhibition
Inhibition of virus infection in primary human hepatocytes
0.3 μM
EC50
Mammalian: 100 h; Yeast: >20 h; E. coli: >10 h
PaperA peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. | Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R. | Antiviral Res. 2010 May;86(2):172-9. | DOI:10.1016/j.antiviral.2010.02.316 | PMID:20156485 PMID20156485 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/20156485/
FIRST PREV 1 2 3 NEXT LAST
Showing 5 records on this page · Page 2 of 3